Literature DB >> 8096062

Vaccination of mice with the protective F3G3 antigen of Toxoplasma gondii activates CD4+ but not CD8+ T cells and induces Toxoplasma specific IgG antibody.

V Brinkmann1, J S Remington, S D Sharma.   

Abstract

A major cytoplasmic Toxoplasma gondii (T. gondii) antigen recognized by monoclonal antibody F3G3 (F3G3-Ag), as well as two surface antigens recognized by monoclonal antibodies 2G11 and 1E11 respectively (2G11-Ag; 1E11-Ag), were isolated from crude Toxoplasma sonicates using affinity chromatography. Purified F3G3-Ag induced long term protection against Toxoplasma infection in mice and induced Toxoplasma specific IgG antibody. CD4+ but not CD8+ T cells from immune animals proliferated and produced IL-2 upon restimulation with either Toxoplasma sonicate or F3G3-Ag in vitro. Furthermore, CD4+ T cells from mice immunized with F3G3-Ag responded to purified 2G11- and 1E11-Ag. In contrast, CD4+ T cells from mice immunized with 2G11-Ag responded to Toxoplasma sonicate and 2G11-Ag, but not to F3G3- or 1E11-Ag. The results may indicate that the protective F3G3-Ag shares immunogenic epitopes present also on 2G11- and 1E11-Ag, since the F3G3-Ag used for the vaccination did not contain detectable amounts of 2G11- or 1E11-Ag, and none of the antigens displayed any mitogenicity. Taken together the results show that the cytoplasmic F3G3-Ag of T. gondii induces CD4+ T helper cells, Toxoplasma specific IgG antibodies and long term protection against Toxoplasma infection, but does not induce detectable sensitization of the CD8+ T cell compartment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096062     DOI: 10.1016/0161-5890(93)90064-i

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris.

Authors:  Huaiyu Zhou; Qinmin Gu; Qunli Zhao; Jiaqin Zhang; Hua Cong; Ying Li; Shenyi He
Journal:  Parasitol Res       Date:  2006-10-21       Impact factor: 2.289

3.  Detection of a novel 40,000 MW excretory Toxoplasma gondii antigen by murine Th1 clone which induces toxoplasmacidal activity when exposed to infected macrophages.

Authors:  G Reichmann; S Stachelhaus; R Meisel; M N Mévélec; J F Dubremetz; H Dlugonska; H G Fischer
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

4.  Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases acute virulence in mice.

Authors:  C Mercier; D K Howe; D Mordue; M Lingnau; L D Sibley
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Comparison of protective immune responses to apicomplexan parasites.

Authors:  Sonja Frölich; Rolf Entzeroth; Michael Wallach
Journal:  J Parasitol Res       Date:  2011-08-18

6.  Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.

Authors:  Li-Tian Yin; Hai-Xia Hao; Hai-Long Wang; Jian-Hong Zhang; Xiao-Li Meng; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

7.  Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice.

Authors:  Hai-Long Wang; Tie-E Zhang; Li-Tian Yin; Min Pang; Li Guan; Hong-Li Liu; Jian-Hong Zhang; Xiao-Li Meng; Ji-Zhong Bai; Guo-Ping Zheng; Guo-Rong Yin
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

8.  Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondii

Authors:  Jalal Babaie; Samira Amiri; Robab Homayoun; Ebrahim Azimi; Reyhaneh Mohabati; Mahboobe Berizi; M. Reza Sadaie; Majid Golkar
Journal:  Iran Biomed J       Date:  2017-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.